We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+6.87%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$9.54B
AUM Growth
+$55.8M
Cap. Flow
-$1.48B
Cap. Flow %
-15.48%
Top 10 Hldgs %
82.65%
Holding
142
New
10
Increased
13
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$28.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.1M
3
MRUS
Merus
MRUS
+$9.82M
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$6.94M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.88M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$274M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
3
OMER icon
Omeros
OMER
+$11.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.52M
5
IMGN
Immunogen Inc
IMGN
+$9.01M

Sector Composition

Rank Sector Weight
1 Healthcare 86.04%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.9B
$1.88B 19.7%
23,498,697
+237
+0% +$18.4K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$1.75B 18.32%
43,238,967
+3,700
+0% +$141K
ABBV icon
3
AbbVie
ABBV
$468B
$890M 9.33%
14,373,538
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$5.08B
$796M 8.34%
24,516,738
+302,900
+1% +$10.1M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$764M 8.01%
6,543,295
+696
+0% +$98.8K
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.9B
$374M 3.92%
4,806,483
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$354M 3.71%
13,668,866
+9,034
+0.1% +$240K
DBVT
8
DBV Technologies
DBVT
$914M
$180M 1.88%
550,956
– –
ACOR
9
DELISTED
Acorda Therapeutics
ACOR
$93.4M 0.98%
30,509
– –
CERS icon
10
Cerus
CERS
$566M
$84.6M 0.89%
13,553,275
– –
ONCE
11
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$67.4M 0.71%
1,318,341
+55,959
+4% +$2.39M
BLCM
12
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$63.1M 0.66%
486,565
– –
ONC
13
BeOne Medicines Ltd
ONC
$42.4B
$57M 0.6%
1,912,680
– –
HRTX icon
14
Heron Therapeutics
HRTX
$60.4M
$51.6M 0.54%
2,857,250
-50,534
-2% -$987K
NGNE icon
15
Neurogene
NGNE
$773M
$51.3M 0.54%
387,624
– –
NVTA
16
DELISTED
Invitae Corporation
NVTA
$48.4M 0.51%
6,554,967
– –
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.44B
$42.6M 0.45%
15,010,534
– –
NBIX icon
18
Neurocrine Biosciences
NBIX
$15.5B
$40.7M 0.43%
895,422
– –
ARAV
19
DELISTED
Aravive, Inc. Common Stock
ARAV
$30.1M 0.32%
453,900
-79,360
-15% -$4.51M
AAAP
20
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$25.2M 0.26%
833,089
+218,056
+35% +$6.94M
XNPT
21
DELISTED
XENOPORT, INC.
XNPT
$24.5M 0.26%
3,475,672
– –
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$23.6M 0.25%
609,166
– –
SGMO
23
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$23.5M 0.25%
4,055,876
– –
NTLA icon
24
Intellia Therapeutics
NTLA
$1.8B
$22.7M 0.24%
+1,062,120
New +$28.3M
EXEL icon
25
Exelixis
EXEL
$13.4B
$20.1M 0.21%
2,580,000
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2016 Portfolio in Review

As of Q2 2016, Julian Baker held 142 positions worth $9.54B, up 0.59% from $9.48B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker withdrew a net $1.48B in Q2 2016, closing 7 positions and reducing 15 holdings. Its most notable exit was ANACOR PHARMACEUTICALS INC COM, an estimated $274M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 82% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in Intellia Therapeutics worth $22.7M.

  • Julian Baker's largest Q2 2016 buy was Intellia Therapeutics: 1,062,120 shares worth $22.7M.
  • Julian Baker added most to Acadia Pharmaceuticals in Q2 2016, an estimated $10.1M increase.
  • Julian Baker's biggest Q2 2016 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $15.9M.
  • Julian Baker fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $274M.
  • Julian Baker's ten largest holdings make up 83% of its $9.54B portfolio in Q2 2016.
  • Julian Baker opened 10 new positions and closed 7 in Q2 2016.
  • Julian Baker's portfolio value rose 0.59% quarter-over-quarter to $9.54B.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.